NCT02381535View on ClinicalTrials.gov

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 22, 2015

Primary Completion Date

April 24, 2020

Study Completion Date

April 24, 2020

Conditions
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
DRUG

Cisplatin

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Onalespib

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (2)

06520

Yale University, New Haven

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02381535 - Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin | Biotech Hunter | Biotech Hunter